Companies · Biotechnology

WaferGen Bio-systems, Inc.

FREMONT · Biotechnology

Diligence memoA one-page analyst read on WaferGen Bio-systems, Inc. — recommendation, valuation, rhythm, risks.
$59.7M
Total raised · real
5
Rounds
0.4×
Latest step-up
Top 17%
Sector rank · raised
Series B
Latest stage · inferred · Tue Aug 27 2013 00:00:00 GMT+0000 (Coordinated Universal Time)

WaferGen Bio-systems, Inc. looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 0.76× the median modeled value of Series B Biotechnology companies in 2013–2015 (77 peers) — value vs value, same stage and era.
  • Within the normal band (76% of peer median) for its niche.
Dormant
  • Last raise 12.8 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

WaferGen Bio-systems, Inc. is one of 4293 Biotechnology companies tracked from FREMONT. By capital raised it ranks in the upper tier (ahead of 84% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$500M$1.0B$1.5B$2.0BSeries A · 2009-05-28 Raised $6.3M (real) Modeled valuation $226M (est)$6.3M$226MSeries A2009Series A · 2009-05-28 Raised $4.1M (real) Modeled valuation $149M (est)$4.1M$149MSeries A2009Series A · 2009-11-11 Raised $5.1M (real) Modeled valuation $184M (est)$5.1M$184MSeries A2009Series B · 2011-05-25 Raised $31M (real) Modeled valuation $1.2B (est)$31M$1.2BSeries B2011Series B · 2013-08-27 Raised $14M (real) Modeled valuation $542M (est)$14M$542MSeries B2013+$4.1M+$5.1M+$31M+$14MCumulative $60M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$6.3M · 2009
Series A extension$4.1M · 2009
Series A extension$5.1M · 2009
Series B$30.6M · 2011
Series B extension$13.7M · 2013

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.

Modeled valuation trajectory
$542.5M
Base estimate est.
$27.3M
Conservative case
$2.1B
Upside case
$75.9M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ba $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Series A · modeled $226.4M · 2009-05-282009Series A · modeled $149.3M · 2009-05-28Series A · modeled $183.8M · 2009-11-11Series B · modeled $1.2B · 2011-05-25Series B · modeled $542.5M · 2013-08-272013
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
54%
Survival probability
36% low · 66% high
1.54×/yr
Annual markup
1.86×/yr upside case
6.0 yr
Elapsed time used
12.8 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
13 mo
Avg between rounds
$14.0M/yr
Capital velocity
17.1 yr
On record since
2009
First round
5
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 8.3× above median
This company$59.7M
Sector median$7.2M
Latest round — vs other Series B rounds in sector (real $, this stage) 0.8× of median
This company$13.7M
Sector median$17.5M
Modeled value — vs sector median (estimate, all stages) 8.5× above median
This company$542.5M
Sector median$64.2M

Raised more than 84% of sector peers (real $). Modeled value above 84% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #48 of 77.

This companyCohort peer
$100.0M$1.0B$10.0B$10.0M$100.0MCapital raised (log)BioAtla,LLC · Series B Raised $47.9M · modeled $1.5B (est)Scholar Rock LLC · Series B Raised $36.3M · modeled $1.4B (est)Oligasis, LLC · Series B Raised $35.8M · modeled $1.3B (est)Alector LLC · Series B Raised $32.3M · modeled $1.3B (est)Gelesis Inc · Series B Raised $37.7M · modeled $1.3B (est)Prosetta Biosciences Inc. · Series B Raised $31.1M · modeled $1.2B (est)Stem Cell Therapeutics Corp · Series B Raised $30.3M · modeled $1.2B (est)Tenex Health, Inc. · Series B Raised $57.4M · modeled $1.2B (est)Aquesys Inc · Series B Raised $49.5M · modeled $1.2B (est)4Tech, Inc. · Series B Raised $62.3M · modeled $1.1B (est)Lorus Therapeutics Inc · Series B Raised $28.3M · modeled $1.1B (est)Kallyope, Inc. · Series B Raised $28.1M · modeled $1.1B (est)WaferGen Bio-systems, Inc. (this company) Raised $59.7M · modeled $542.5M (est)WaferGen Bio-systems, Inc.
CompanyStageRaised · realValue · estvs peer med.
BioAtla,LLCSeries B$47.9M$1.5B2.16×
Scholar Rock LLCSeries B$36.3M$1.4B2.01×
Oligasis, LLCSeries B$35.8M$1.3B1.88×
Alector LLCSeries B$32.3M$1.3B1.79×
Gelesis IncSeries B$37.7M$1.3B1.75×
Prosetta Biosciences Inc.Series B$31.1M$1.2B1.73×
Stem Cell Therapeutics CorpSeries B$30.3M$1.2B1.68×
Tenex Health, Inc.Series B$57.4M$1.2B1.66×
Aquesys IncSeries B$49.5M$1.2B1.66×
4Tech, Inc.Series B$62.3M$1.1B1.60×
Lorus Therapeutics IncSeries B$28.3M$1.1B1.57×
Kallyope, Inc.Series B$28.1M$1.1B1.56×
WaferGen Bio-systems, Inc. this companySeries B$59.7M$542.5M0.76×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$6.3M2009-05-28$28.5M$226.4M90%
Series A$4.1M2009-05-28$18.8M$149.3M90%
Series A$5.1M2009-11-11$23.1M$183.8M90%
Series B$30.6M2011-05-25$169.7M$1.2B90%
Series B$13.7M2013-08-27$75.9M$542.5M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$6.3M2009-05-28
    • First recorded raise — entered as Series A.
  2. Series A$4.1M2009-05-28
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.5× smaller than the prior — bridge or down round.
  3. Series A$5.1M2009-11-11
    • Came back fast: 5 mo vs the ~14 mo sector norm.
    • Round roughly the size of the prior one.
  4. Series B$30.6M2011-05-25
    • Raised 18 mo later, in step with the ~14 mo sector norm.
    • Round 6.0× larger than the prior — scaling up.
  5. Series B$13.7M2013-08-27
    • Raised again after 27 mo — slower than the ~14 mo sector norm.
    • Round 2.2× smaller than the prior — bridge or down round.
Intelligence
2014 ~Q3
Modeled next raise · ~13mo cadence
$13.7M
Modeled next size est.range $13.7M$21.9M
0.4×
Last step-up
$14.0M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Robert J Hariri4 other2011-05
Scott Davidson2 other2013-08
Alnoor Shivji1 other2009-05
Robert Coradini1 other2011-05
Donald Dean Huffman2011-05
Ivan Dean Trifunovich2013-08
Joel Dean Kanter2011-05
John Dean Harland2013-08
Joseph Dean Pesce2013-08
Makoto Dean Kaneshiro2011-05
Mona Dean Chadha2011-05
Raymond Dean Hautamaki2009-11
R. Dean Hautamaki2011-05
Timothy Dean Triche2011-05
Registry & provenance

WaferGen Bio-systems, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1368993
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Cryoport, Inc.BiotechnologySeries B$52.9M$992.2Mnetwork1 shared operator · same sector · same stage
Celularity IncBiotechnologySeries B$41.8M$8.1Mnetwork1 shared operator · same sector · same stage
Human Longevity, Inc.BiotechnologySeries B$59.0M$399.4Msame sector · same stage
NanoCellect Biomedical, Inc.BiotechnologySeries B$58.6M$322.9Msame sector · same stage
Senseonics, IncBiotechnologySeries B$60.8M$396.9Msame sector · same stage
Spotlight Therapeutics, Inc.BiotechnologySeries B$61.6M$688.5Msame sector · same stage
Kona Medical, Inc.BiotechnologySeries B$61.6M$396.9Msame sector · same stage
Cue Biopharma, Inc.BiotechnologySeries B$57.4M$429.6Msame sector · same stage
Frequently asked
How much funding has WaferGen Bio-systems, Inc. raised?
WaferGen Bio-systems, Inc. has raised approximately $59.7M in disclosed capital across 5 recorded financing rounds, aggregated from public filings.
What is WaferGen Bio-systems, Inc.'s estimated valuation?
Provath's modeled valuation for WaferGen Bio-systems, Inc. is approximately $542.5M (modeled range $27.3M–$2.1B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is WaferGen Bio-systems, Inc. at?
WaferGen Bio-systems, Inc.'s latest modeled financing stage is Series B. Its most recent recorded round closed around Tue Aug 27.
What does WaferGen Bio-systems, Inc. do and where is it based?
WaferGen Bio-systems, Inc. operates in the Biotechnology sector, based in FREMONT.
Explore related

See where WaferGen Bio-systems, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at WaferGen Bio-systems, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.